Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after a treatment-free interval.

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Equities researchers at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Researchers confirmed that black-legged ticks (Ixodes scapularis) can trigger alpha-gal syndrome in humans. A 10-year ...

Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.